Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | AGXT | P21549 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21638945 | 0.96 | TSHR (0.43) | TSHRIDO1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL2237483 | 0.94 | TSHR (0.41) | TSHRIDO1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL2126979 | 0.80 | TSHR (0.45) | TSHROPRM1LMNASLC6A2SLC6A3 | |
| SCHEMBL9020639 | 0.77 | TSHR (0.40) | TSHRIDO1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL9720395 | 0.76 | CA1 (0.41) | IDO1CYP2C19OPRM1OPRL1MEN1 | |
| SCHEMBL5176709 | 0.76 | KMT2A (0.44) | TSHRSLC1A3SLC1A2SLC1A1CYP1A2 | |
| SCHEMBL6831608 | 0.74 | CA2 (0.44) | TSHRALDH1A1CA12CA1CA2 | |
| SCHEMBL10942039 | 0.73 | TSHR (0.44) | TSHRIDO1OPRM1OPRD1OPRK1 | |
| SCHEMBL19094203 | 0.73 | TSHR (0.40) | TSHRIDO1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL2454671 | 0.73 | TSHR (0.50) | TSHROPRM1DDB1CRBNSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4514794-B1 | FGFR2 INHIBITOR COMPOUNDS | LILLY CO ELI (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20250263409-A1 | FGFR2 INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2025-08-21 | — | — | US | disclosed |
| EP-4522607-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF-kB INDUCING KINASE | JANSSEN Pharmaceutica NV (BE) | 2025-03-19 | — | — | EP | disclosed |
| EP-4514794-A1 | FGFR2 INHIBITOR COMPOUNDS | Eli Lilly and Company (US) | 2025-03-05 | — | — | EP | disclosed |
| EP-4511375-A1 | BICYCLIC COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| CN-119421882-A | FGFR2 inhibitor compounds | 伊莱利利公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-119317626-A | Pyrrolidone derivatives as inhibitors of NF- κb-induced kinase | 詹森药业有限公司 | 2025-01-14 | — | — | CN | disclosed |
| CN-119156381-A | Compounds and methods for treating cancer | 上海睿跃生物科技有限公司 | 2024-12-17 | — | — | CN | disclosed |
| EP-4456895-A2 | HETEROARYL COMPOUNDS AS INHIBITORS OF IRAK4, COMPOSITIONS AND APPLICATIONS THEREOF | Accro Bioscience (HK) Limited (HK) | 2024-11-06 | — | — | EP | disclosed |
| CN-118239938-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2024-06-25 | — | — | CN | disclosed |
| US-11612606-B2 | 8-aminoisoquinoline compounds and uses thereof | GENENTECH, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| EP-3676297-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | Denali Therapeutics Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019046779-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| WO-2018137573-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018107415-A1 | HYDROXY ISOXAZOLE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-06-21 | — | — | WO | disclosed |
| WO-2017201683-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-30 | — | — | WO | disclosed |
| EP-3154976-A2 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | Merck Sharp & Dohme Corp. (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-3099695-A1 | COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2016-12-07 | — | — | EP | disclosed |
| WO-2015113452-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-08-06 | — | — | WO | disclosed |
| WO-2008147547-A1 | SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263409-A1 | FGFR2 INHIBITOR COMPOUNDS | FGFR2, FGFR1, FGFR3 | TSHR 1062/4885IDO1 3677/4885SLC1A3 1711/4885 |
| US-11612606-B2 | 8-aminoisoquinoline compounds and uses thereof | PHKG1, MAP4K5, HIPK1 | TSHR 4838/4885IDO1 1237/4885SLC1A3 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.